TWO DOSES STUDY TO COMPARE THE SAFETY OF SDZ RAD IN HEART/LUNG TRANSPLANT

SDZ RAD研究是一项随机、双盲、分层(主要诊断为胰腺囊性纤维化不足和非囊性纤维化)的交叉试验，旨在测试SDZ RAD在稳定的肺和心/肺移植受者中的耐受性、安全性、药代动力学、药效学和代谢。试验参与者接受了两种不同的单次口服SDZ RAD(0.035和0.1 mg/kg，最大分别为2.5和7.5 mg)。SDZ RAD的两个管理部门之间有大约15天的冲销期。

This study of SDZ RAD was a randomized, double-blind, stratified(to primary diagnosis of pancreatic insufficient cystic fibrosis and non cystic fibrosis), crossover trial designed to test the tolerability, safety, pharmacokinetics, pharmacodynamics, and metabolism of SDZ RAD in stable lung and heart/lung transplant recipients. Trial participants received two different single oral doses of SDZ RAD (0.035 and 0.1 mg/kg, up to a maximum of 2.5 and 7.5 mg respectively). There was a washout period of approximately 15 days between the two administrations of SDZ RAD.